Compliance in the C-Suite

Michael Volkov, CEO
Volkov Law Group LLC

The ongoing debate whether certain executives are “too big to jail” misses the most important trend in corporate governance – namely, that criminal conduct is rising in the C-Suite. Viewed from a broad perspective, since 2000, the trend of C-Suite misconduct is unmistakable, and government prosecutors have paid greater attention while devoting more resources to the prosecution of rogue executives. At the same time, although policymakers, regulators and prosecutors have intensified their focus on internal compliance programs, the potential impact of those programs on C-Suite misconduct and culture seems to have been overlooked.

Since July 2002, the Department of Justice has convicted over 200 Chief Executive Officers and Presidents, over 120 Vice Presidents and 53 Chief Financial Officers. These statistics, by themselves, paint a damning picture of ethics and compliance in the C-Suite. Meanwhile, a 2006 Compliance and Ethics Leadership Council study of major compliance scandals from 1999 to 2005 found that significant compliance violations almost always fell at the feet of a senior manager. According to CELC’s findings, in 46 percent of the incidents studied, senior managers knew about alleged improper conduct, and in another 40 percent of the incidents studied, the senior managers committed alleged improper conduct themselves. Taken together, the CELC findings suggest that more than 4 out of 5 senior managers either knew about or committed the crimes at issue.

A subsequent study of corporate fraud conducted by KPMG found even more disturbing trends: in particular, an accelerating trend in criminal behavior perpetrated by Chief Executive Officers. From January 2008 to December 2010, KPMG found that 26 percent of observed corporate frauds involved the CEO, up from 11 percent in 2007. Among C-Suite executives, the involvement of CEOs in fraud activity was only exceeded by the involvement of senior finance executives, who were associated with 32 percent of cases. Board level perpetrators increased from 11 to 18 percent between 2007 and 2011. Meanwhile and in a consistent vein, FBI Director Robert Mueller testified in 2011 that the FBI then had 667 ongoing probes into corporate fraud, and 1700 open cases of securities fraud.

---


2 Charting a New Course: Measuring and Monitoring the Effectiveness of Compliance and Ethics Programs (Corporate Executive Board - Compliance and Ethics Leadership Council 2006) p. 9

3 KPMG gathered data from fraud investigations conducted by the firms' forensic specialists around the world from January 2008 to December 2010. In all, 348 cases from 69 countries were analyzed. http://www.kpmg.com/IS/is/utgefidefni/greinar-og-utgefid/Documents/Who_is_the_typical_fraudster.pdf

4 Id.

Although there is ample evidence to suggest an increasing enforcement focus on C-Suite executives, it is far less clear that the risks of C-Suite misconduct are being proactively addressed within companies. In too many instances, senior executives appear to have the means, the motive and the opportunity to engage in criminal fraud and other misconduct.

An important motive for accounting fraud, in particular, is manifest in executive pay structures that base incentive compensation on short-term corporate income. Multiple studies have documented the growing number of companies which structure their executive incentives in this way.6 Such incentives can feed the motivation of personal greed among senior executives, and amplify it through intense pressures to reach tough profit and budget targets.7 The KPMG survey also highlights how weakening control structures have made the opportunity to commit fraud easier.8 Organizations contribute to fraud when they fail to detect or respond to lapses or gaps in controls, as much as by setting overly onerous performance targets. Less robust controls, and fewer resources to monitor the controls, allow for greater exploitation by fraudsters.

In the 1980s and 1990s, prosecutors went after notorious white collar crimes and scandals, including the Wall Street criminal prosecutions with the mass arrests orchestrated by then U.S. Attorney Rudy Giuliani, and the Savings and Loans scandals of the 1980s and 1990s. Starting in 2000, however, with the fall of Enron, WorldCom, Adelphi, and continuing up until today, white collar prosecution has grown more and more recognized as a criminal enforcement priority, across both Democrat and Republican administrations. Yet the prevalence of crimes committed by top executives continues unabated. The fact that C-Suite crime continues to present a serious problem raises a question about additional measures that should be taken, beyond law enforcement, to address C-Suite misconduct and culture problems internally by corporations.

**The Risks of C-Suite Misconduct: Some Recent Examples of Criminal Prosecutions**

The Department of Justice’s focus on corporate executives reflects public opinion and political priorities. The business community now faces a skeptical public, one with little faith in the overall ethics and social responsibility of corporations and their executives. This perception (and reality) of corporate malfeasance has been underscored by press reports of corporate governance failures involving bribery, money laundering controls,9 healthcare fraud10 and LIBOR price-fixing scandals.11

---


While history will resolve the question of whether prosecutors failed to charge financial companies and executives responsible for the financial meltdown, the Obama Administration has subsequently increased scrutiny of high-level corporate officers and employed a number of new, aggressive tools to do so, including the use of wiretaps to catch insider trading executives and the regular use of “ambush” interviews as a means to enlist the cooperation of potential defendants in government investigations.  

In another area of focus, the Obama Administration has recently made healthcare fraud a priority, and increased pressure against high-level executives for any whiff of misconduct. In early 2013, for example, a criminal trial against five executives from WellCare began in federal court. Sitting at the defense table were the former CEO and President (and Chairman of the Board), the CFO, two Vice Presidents and the General Counsel. The executives allegedly concocted a scheme to game the Medicaid system, and fraudulently to divert hundreds of millions of dollars. The scheme came to light when a whistleblower reported the misconduct and then agreed to wear a wire and record over 650 hours of conversations among the executives, including the general counsel.

Corporate executives have lately been prosecuted and sentenced to significant periods of incarceration for foreign bribery, fraud, illegal cartels and other criminal offenses. Some high-profile examples include the president of one company who was sentenced to 180 months (15 years) imprisonment for paying bribes to foreign government officials in Haiti; a former mortgage industry executive who was accused of masterminding one of the largest bank frauds.

---


14 Id.

schemes in history, and sentenced to 30 years in prison;\(^{16}\) 22 corporate executives who were involved in a massive antitrust cartel in the LCD-display industry, and were sentenced to terms of imprisonment totaling over 4,781 days;\(^{17}\) and of course, Bernie Madoff, who was sentenced to 150 years imprisonment.

The Department of Justice has dusted off the “responsible corporate officer” (RCO) doctrine to target executives in the healthcare industry, coupled with unprecedented enforcement of civil exclusion laws.\(^{18}\) Even those members of the C-Suite who are not actively involved in illegal conduct may be prosecuted, and incarcerated, for their roles in such cases.

Under the RCO doctrine, four corporate executives from Synthes were incarcerated for misdemeanor violations under the FDCA when they knew about illegal conduct but failed to take any steps to stop or prevent the conduct from occurring again. The company had conducted a series of non-approved clinical trials of its new bone cement used in orthopedic surgeries. The FDA warned Synthes not to promote the bone cement for certain spine surgeries, but the company, with the executives blessing, pushed ahead anyway. At least five patients who had the drug injected into their spines died on the operating-room table. The company and its executives ignored evidence of potential lethal consequences, and even went so far as to brush away scientists' cautions that the cement could cause fatal blood clots.\(^{19}\) At sentencing, the federal judge expressed his frustration with the conduct of each of the corporate executive defendants, and even ordered one of them “stepped-back” and sent him to jail on the day of sentencing.\(^{20}\)

---


\(^{18}\) The “responsible corporate officer” doctrine provides that a “corporate agent, through whose act, default, or omission the corporation committed a crime” in violation of the Food, Drug, and Cosmetic Act (“FDCA”) may be held criminally liable for the wrongdoing of the corporation “whether or not the crime required ‘consciousness of wrongdoing ’ ” by the agent. United States v. Park, 421 U.S. 658, 670 (1975). Criminal liability under the RCO doctrine extends to both the corporate agents who committed the criminal act and “those who by virtue of their managerial positions or other similar relation to the actor could be deemed responsible for its commission.” Id. (emphasis added). A corporate officer may therefore be guilty of a crime without “knowledge of, or personal participation in,” the underlying fraudulent conduct. Id.


\(^{20}\) In December 2011, Thomas B. Higgins, the president of Synthes’ Spine Division, was sentenced to nine months in prison for violations of FCDA. See United States v. Higgins, 2011 WL 6088576 (E.D. Penn. 2011) Thomas B. Higgins, the president of Synthes’ Spine Division, pled guilty as a responsible corporate officer to the “introduction into interstate commerce of adulterated and misbranded medical devices.” Id. at *1. Higgins maintained that he did not know his actions were illegal at the time and did not intend to violate the law. Id. at *9. Higgins was sentenced to nine months incarceration. Richard Bohner, the Vice President of Operations, who was the senior Synthes executive with overall responsibility for regulatory compliance matters during the relevant period, also ended up
In the case of Purdue Pharma, a manufacturer of the painkiller OxyContin, three of its top executives (its president, chief legal officer and former chief medical officer) pleaded guilty to charges of misleading the public about the drug’s risks. Purdue Pharma LP and the executives were fined a total of $634 million. As part of their scheme, the executives designed and implemented a marketing strategy which was aimed at soft-pedaling the addictive risks of OxyContin. Starting in 1996, Purdue Pharma began holding focus groups with doctors about its new long-lasting painkiller. Many of the doctors said they were reluctant to prescribe the drug because they worried about its potential for abuse. In response, the company's sales representatives began misleading physicians about OxyContin. They said, for instance, that the drug produced no euphoric feelings for users and that users suffered no withdrawal symptoms when they stopped taking it. Within a few years, the use of the drug exploded, and led to one of the nation's worst prescription-drug failures. The former president of Purdue Pharma was excluded from the healthcare industry for 12 years.

Enforcement examples like these have created an understandable climate of fear in corporate C-Suites. Corporate leaders and boards should be concerned about C-Suite misconduct and turn their attention to compliance at the highest levels of the company. The risk of failure is too great -- prosecutors reaching into the corporate C-Suites handing out grand jury subpoenas, threatening indictments, and arresting corporate executives can put the future of an entire company in jeopardy.

C-Suite Compliance: An Ignored Risk and Disastrous Consequences

In this climate of fear, some companies have increased their focus on proactive compliance programs as a means to reduce risk of prosecution. Recent surveys of corporate compliance professionals show that companies are spending more money on their compliance programs. This is a welcome development.

---

pleading guilty for failing to either prevent or promptly correct Synthes’ illegal test marketing and promotion. Boehner was sentenced to eight months incarceration. United States v. Boehner, 2011 WL 6371826 (E.D. Pa. 2011). Phil Milford and Sophia Pearson, Ex-Synthes Executive Gets Eight-Month Term in Bone-Cement Case, Bloomberg.com, Dec. 14, 2011. In addition to Higgins and Boehner, two other Synthes executives, Michael Huggins and John Walsh were sentenced to jail for nine months and five months, respectively. Id. Moreover, Synthes agreed to plead guilty, sell the device, and pay a $23.5 million fine to settle the case. Id.


22 Id.

This trend, however, has not focused on compliance in the C-Suite. Broad brushstrokes of compliance programs frequently focus on creating a “culture of compliance” or communicating a “tone at the top” to others outside the C-Suite. There has not been a complementary focus on compliance within the C-Suite itself.

The reason for this omission is basic. It is too often simply assumed that efforts to communicate a “tone at the top” (i.e., an ethical workplace atmosphere fostered by corporate leadership) demonstrate a company’s commitment to ethical conduct at the C-Suite level. This assumption means that internal controls and compliance programs may simply ignore the C-Suite officers. In many corporate compliance programs, beyond broad statements of commitment to ethical conduct, the only meaningful detail relating to C-Suite compliance is the requirement that the company’s board and the officers participate in a one-hour training program.

The potential harm to a company which ignores C-Suite compliance risks is significant. In the same way that ethical “tone at the top” has the potential to filter down to other levels of a company, the absence of a meaningful commitment by the C-Suite to participate in a compliance program also sends a significant message throughout the organization: It suggests a fundamental contradiction, which can quickly evolve into a culture of cynicism, rather than fostering a culture of compliance.

A striking example of this contradiction occurred in a non-criminal context when Best Buy’s CEO and its Chairman were forced to resign because of the Chairman’s failure to report to the board his knowledge of the CEO’s affair with a 29 year-old subordinate. The Chairman was neither trained nor aware of the proper protocol when he learned about the CEO’s alleged affair. Instead of reporting the matter as required under the Best Buy compliance program, the Chairman went and asked the CEO whether the allegation was true. The CEO denied the matter and the Chairman let the matter drop. The Chairman’s blatant disregard of the Best Buy compliance program occurred in an environment where Best Buy’s ethics program included many best practices: an ethicist was on its board of directors; the ethics officer, Kathleen Edmond, had a website promoting her work and outlook; and the company was committed to transparency and compliance at every level except the C-Suite.

**C-Suite Ethics and Compliance: A Proposed Solution**

The solution to C-Suite ethics and compliance requires a multi-faceted strategy. It is easy to identify the problem, but a much greater challenge to implement an effective solution, since this requires close coordination among the board, senior management and the chief compliance officer. There are three steps which need to be addressed.

---

Step One: Redefine the Board’s Compliance and Ethics Role:

Corporate governance at the board level is coming under increasing scrutiny. No longer can a board meet a few times a year, review general documents, and relax behind the protection of minimum standards set forth under the Caremark decision and the business judgment rule. Just as corporate executives need to step-up their compliance efforts, so do corporate boards.26

Corporate governance standards are changing – more shareholders are focusing on deficiencies at the board level, especially in shareholder litigation for corporate misconduct. If the Board is not committed to compliance oversight (including at the C-Suite level), then neither will the company be committed.

Corporate boards need to conduct a rigorous self-examination of their own performance and the steps needed to minimize compliance risks. With a goal of ensuring compliance and ethical conduct, many boards are beginning to take protective steps: creating a strong independent board with monitoring functions, nominating and appointing independent and qualified directors, creating working committees, implementing a robust compliance and ethics program which stresses ethical conduct and is strictly enforced.

With respect to building an effective compliance and ethics program, the board needs to focus on two simple questions: (1) How can we get the information we need?; and (2) How can we oversee the compliance and ethics function within the company?

The board needs to start by setting up a “compliance committee.” The old model of layering compliance on top of the audit committee’s responsibility is a relic of the past, when financial certifications and accuracy were the focus of compliance in the Sarbanes-Oxley world. The compliance universe is a lot more expansive now than just under Sarbanes-Oxley. More companies now have implemented a stand-alone compliance committee. A specialized board committee focused on risk management, compliance and ethics is the first and most important step in building a C-Suite culture of compliance.

With the compliance committee in hand, the board needs to establish a working protocol with the Chief Compliance Officer (CCO) of the company. An effective working relationship will establish meaningful checks and balances in the company. Information is the key to compliance, and making sure that the CCO brings to the compliance committee important information in a timely fashion is critical. The protection of the CCO’s role and ability to report directly to the board is paramount to this process. In some respects, the CCO will become a direct employee of the board, as explained in Step Two below.


26 See generally, Deloitte Board Governance, available at http://www.corpgov.deloitte.com/site/us/board-governance/isessionid=kNZWRZn7DbSysszfJlT1BNkKtT1M1J3pmRtnjz2qORy4Zc4Qv2tsL-4983358921698926776.
A proper relationship between the board and the CCO requires the board to protect the CCO from retaliation from senior management, and to establish clear reporting expectations and requirements.

In addition to these basic tasks, the board needs to take a hard look at its CEO and the compensation for the CEO. In too many companies, CEOs are treated as superstars who are untouchable, and who are paid at rates that are disproportionate to the company’s pay structure. Corporate governance reform also means reforming CEO compensation so that it is tied to long-term results, including ethical performance, rather than short-term financial results.

**Step Two: Empowering an Independent Chief Compliance Officer**

Many argue that prosecution of individual senior executives is the only real deterrent to corporate criminal behavior, and the only way to bring about change in corporate behavior. There is no question that prosecution of corporate executives increases incentives for corporate compliance. Companies recognize another important component of corporate compliance: an empowered C-Suite CCO.

The most significant trend in the last decade has been the increasing recognition for the importance of the CCO in a corporation. As prosecution risks have increased, so has the role of the CCO. Companies are fast recognizing the value of elevating a CCO, and protecting his independence through direct reporting authority to the board or a board committee.

The evolution of the role of CCO has been the result of a variety of forces – increased government prosecutions, adoption of specific guidance in the United States Sentencing Guidelines, requirements imposed by Health and Human Services in corporate integrity agreements, and industry education efforts.

Until the last few years, many companies added compliance oversight to the responsibility of their general counsels. A 2009 survey of companies found that nearly half of the responding companies followed this pattern. More recently, companies have started to recognize that general counsels should not serve in this dual role of chief legal officer and chief compliance officer, given the different mandates and competencies required by each position. Many in the legal and governance communities have now endorsed the need for splitting the functions of chief legal officer and chief compliance officer.

Recent developments in the corporate world have refocused attention on effective corporate governance and the proper role of the CCO in an organization. Corporate compliance programs are continuing to evolve in response to emerging “best practices” and changes in the business

---

29 In the 2012 PWC State of Compliance Study, the number of CCOs reporting to GCs fell by 6 percent—to 35 percent from 41 percent—in the prior year.
environment. Back as far as 1998, the government encouraged companies to ensure the independence of chief compliance officers:

The OIG believes that there is some risk to establishing an independent compliance function if that function is subordina[te] to the hospital’s [G]eneral [C]ounsel, or comptroller or similar hospital financial officer. Freestanding compliance functions help to ensure independent and objective legal reviews and financial analyses of the institution’s compliance efforts and activities. By separating the compliance function from the key management positions of [G]eneral [C]ounsel or chief hospital financial officer (where the size and structure of the hospital make this a feasible option), a system of checks and balances is established to more effectively achieve the goals of the compliance program.  

In a similar vein, in a September 5, 2003, letter to Tenet Healthcare Corporation, United States Senator Charles Grassley (R-IA) observed:

Apparently, neither Tenet nor (its General Counsel) saw any conflict in her wearing two hats as Tenet’s General Counsel and Chief Compliance Officer . . . . It doesn’t take a pig farmer from Iowa to smell the stench of conflict in that arrangement.

The United States Sentencing Commission set in motion strong incentives for a company to earn credit for an “effective” corporate compliance program by implementing the organizational sentencing guidelines, and by adopting recent amendments to the guidelines in 2010 which specifically required companies to establish a senior level officer responsible for corporate compliance with direct reporting authority to the board.

Specific individual(s) within the organization shall be delegated day-to-day operational responsibility for the compliance and ethics program. Individual(s) with operational responsibility shall report periodically to high-level personnel and, as appropriate, to the governing authority, or an appropriate subgroup of the governing authority, on the effectiveness of the compliance and ethics program. *To carry out such operational responsibility, such individual(s) shall be given adequate resources, appropriate authority, and direct access to the governing authority or an appropriate subgroup of the governing authority.*

---


32 Section 8B2.1 (b) (2) (C), United States Sentencing Guidelines.
In addition to the Sentencing Commission’s 2010 amendments to the guidelines, and in response to specific scandals and prosecutions in the healthcare industry, prosecutors demanded that companies separate the chief compliance functions from the chief legal officer.  

Companies now are embracing the idea of a C-Suite level chief compliance officer, and empowering that officer with adequate resources and real autonomy. Among the many other reasons supporting the elevated CCO, is the likelihood that a C-Suite level officer can more effectively pursue a compliance agenda within the C-Suite, and identify and communicate at that level any related lapses, escalating those to the board where necessary. For example, recently in response to governance failures and legal violations, HSBC and J.P Morgan re-energized their compliance programs by empowering independent CCOs with new reporting authorities and positioning. These innovative solutions to real governance problems reflect a growing trend across many industry sectors: namely, to empower a chief compliance officer as a check and balance against the potential for future C-Suite level misconduct.

**Step Three: C-Suite Compliance Risks and Responses**

An independent chief compliance officer requires adequate resources to operate. Recent FCPA settlements have incorporated compliance program resourcing as an explicit requirement. A similar requirement is also included in the Sentencing Guidelines definition of an “effective” compliance program.

This requirement should be expanded to include resources needed to focus on C-Suite compliance programs and controls. An independent chief compliance officer ought to have the authority and the ability to turn his or her attention to compliance in C-Suite.

Chief Compliance officers are well-suited to this task. They can employ the well-known tools of their profession, starting with an overall risk assessment. The recent FCPA Guidance issued by the Department of Justice and the Securities and Exchange Commission underscored the importance of risk assessment in tailoring an “effective” corporate compliance program.

C-Suite compliance, in particular, requires an independent risk assessment. In response to identified risks, a chief compliance officer can then develop specific policies and procedures and controls, coupled with appropriate training programs, certification requirements and notifications of compliance obligations. Given the gravity of the risks associated with C-Suite misconduct, the compliance officer needs to employ appropriate tools which can reduce the risk and demonstrate the company’s commitment to ethical conduct.

---


In completing this task, the independence and seniority of the chief compliance officer is fundamental to success. It is unrealistic to expect a CCO who is subordinate to the C-Suite hierarchy (and particularly if buried several levels down in management) to be able to influence C-Suite practices, to become aware of C-Suite improprieties, or to be insulated from reprisal in the event that such improprieties manifest. For all of these reasons, the chief compliance officer should report directly to the board on the C-Suite compliance program, preferably through a specific board-level compliance committee which is created at the same time that the board formally undertakes to ensure CCO empowerment and independence. The board committee would then play an active role in the supervision and monitoring of the C-Suite compliance program, to ensure that the program is “effective.”

The independence and empowerment of the chief compliance officer is significant factor in contributing to the overall corporate culture. Where the chief compliance officer is responsible for a meaningful and visible C-Suite compliance program, then employees throughout the company will quickly understand that the commitment to compliance is real, and that no one within the company is really above the law.

The key to corporate integrity is a uniform cultural commitment to justice and ethical conduct. Such culture is more likely to emerge when employees believe that tone at the top is matched by meaningful controls and consistent enforcement, at all levels of the organization.

**Conclusion**

C-Suite risks can have catastrophic consequences to a company. Government prosecutors continue to rack up convictions of C-Suite corporate officers. Yet corporate boards and senior management have too often paid little attention to this issue. Corporate boards can address the issue by ensuring that an empowered and independent CCO heads the compliance function within their organizations. In turn, the role of the CCO should be to advise and assure the board on the design, implementation and monitoring of the company’s compliance program, with a special focus on C-Suite compliance. Given this new focus, corporate boards can demonstrate to senior management, employees and the general public that a company’s commitment to an “ethical culture” is real, and supported by the instrumentality of meaningful controls, an active champion within senior management, and much more effective board oversight.